{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:22:54Z","timestamp":1787966574718,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j intensive care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Remimazolam, an ultra-short-acting benzodiazepine rapidly metabolized by carboxylesterase-1, was developed as a promising alternative for ICU sedation. It was anticipated to overcome the unpredictable accumulation associated with midazolam and the hemodynamic\/metabolic risks of propofol, offering superior hemodynamic stability and potential benefits in reducing postoperative delirium. Its ultra-short, predictable half-life positioned it as an ideal candidate for facile titration in critically ill patients. However, the trajectory of remimazolam's development for long-term ICU sedation faced a critical setback in Japan. Based on results from the ONO-2745-04 Phase II trial conducted on mechanically ventilated postoperative patients, the development program for the ICU indication was halted in 2013. The central safety concern was the unexpected pharmacokinetic failure observed in a subset of patients receiving continuous infusion for 24\u00a0h or longer. Specifically, this subgroup exhibited plasma concentrations of the parent drug far exceeding predicted levels, resulting in significantly delayed awakening and recover. This observation directly challenged the fundamental non-accumulating advantage of the drug. The mechanism is hypothesized to be compromised carboxylesterase-1 activity due to severe critical illness, systemic inflammation, or organ dysfunction\u2014conditions that impair the very non-organ-dependent clearance pathway the drug relies upon. While international experience continues to validate the safe and effective use of remimazolam for short-to-medium-term ICU sedation, the Japanese experience serves as a critical clinical warning. It underscores that even drugs with inherently favorable pharmacokinetic profiles are susceptible to unpredictable parent drug accumulation in the highly heterogeneous and physiologically compromised ICU population during prolonged infusion. Therefore, extreme caution and individualized dosing strategies are warranted for remimazolam use in critically ill patients, especially those with severe systemic dysfunction.<\/jats:p>","DOI":"10.1186\/s40560-026-00849-8","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:43:46Z","timestamp":1768974226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Discontinuation of the development of remimazolam for ICU sedation in Japan: background and rationale"],"prefix":"10.1186","volume":"14","author":[{"given":"Junichi","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"849_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/CCM.0000000000006178","volume":"52","author":"NE Hume","year":"2024","unstructured":"Hume NE, Zerfas I, Wong A, Klein-Fedyshin M, Smithburger PL, Buckley MS, et al. Clinical impact of the implementation strategies used to apply the 2013 pain, agitation\/sedation, delirium or 2018 pain, agitation\/sedation, delirium, immobility, sleep disruption guideline recommendations: a systematic review and meta-analysis. Crit Care Med. 2024;52:626\u201336.","journal-title":"Crit Care Med"},{"key":"849_CR2","volume":"44","author":"N Grillot","year":"2025","unstructured":"Grillot N, Vourc\u2019h M, Hourmant Y, Bouras M, Rozec B, Rouhani A, et al. A phase 2 open-label pilot study of remimazolam for sedation in critically ill patients. Anaesth Crit Care Pain Med. 2025;44:101510.","journal-title":"Anaesth Crit Care Pain Med"},{"key":"849_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01440-9","volume":"28","author":"Z Yao","year":"2023","unstructured":"Yao Z, Liao Z, Li G, Wang L, Zhan L, Xia W. Remimazolam tosylate\u2019s long-term sedative properties in ICU patients on mechanical ventilation: effectiveness and safety. Eur J Med Res. 2023;28:452.","journal-title":"Eur J Med Res"},{"key":"849_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1139872","volume":"14","author":"X Yang","year":"2023","unstructured":"Yang X, Tang Y, Du R, Yu Y, Xu J, Zhang J, et al. Long-term sedation with remimazolam besylate versus propofol in critically ill patients during invasive mechanical ventilation: a study protocol for a multicenter randomized non-inferior trial. Front Pharmacol. 2023;14:1139872.","journal-title":"Front Pharmacol"},{"key":"849_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20946-6","volume":"12","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang J, Yuan S, Huang H. Remimazolam besylate for the sedation of postoperative patients undergoing invasive mechanical ventilation in the ICU: a prospective dose\u2012response study. Sci Rep. 2022;12:19022.","journal-title":"Sci Rep"},{"key":"849_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04760-8","volume":"27","author":"Y Tang","year":"2023","unstructured":"Tang Y, Gao X, Xu J, Ren L, Qi H, Li R, et al. Remimazolam besylate versus propofol for deep sedation in critically ill patients: a randomized pilot study. Crit Care. 2023;27:474.","journal-title":"Crit Care"},{"key":"849_CR7","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1097\/CM9.0000000000002243","volume":"135","author":"Y Tang","year":"2022","unstructured":"Tang Y, Yang X, Shu H, Yu Y, Xu J, Pan S, et al. Remimazolam besylate for sedation of postoperative patients in intensive care units: a phase I, open label, dose-finding study. Chin Med J (Engl). 2022;135:2134\u20136.","journal-title":"Chin Med J (Engl)"},{"key":"849_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ALN.0000000000003103","volume":"132","author":"J Schuttler","year":"2020","unstructured":"Schuttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology. 2020;132:636\u201351.","journal-title":"Anesthesiology"},{"key":"849_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70130","volume":"13","author":"J Hu","year":"2025","unstructured":"Hu J, Zhao Y, Shao L, Zhang W, Wang H, Liu Y, et al. Pharmacokinetic properties and therapeutic effectiveness of remimazolam in ICU patients with mechanical ventilation: a preliminary study. Pharmacol Res Perspect. 2025;13:e70130.","journal-title":"Pharmacol Res Perspect"},{"key":"849_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2020.109899","volume":"66","author":"J Zhou","year":"2020","unstructured":"Zhou J, Leonowens C, Ivaturi VD, Lohmer LL, Curd L, Ossig J, et al. Population pharmacokinetic\/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. J Clin Anesth. 2020;66:109899.","journal-title":"J Clin Anesth"},{"key":"849_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bja.2021.05.027","volume":"127","author":"T Stohr","year":"2021","unstructured":"Stohr T, Colin PJ, Ossig J, Pesic M, Borkett K, Winkle P, et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br J Anaesth. 2021;127:415\u201323.","journal-title":"Br J Anaesth"},{"key":"849_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-025-01431-5","volume":"15","author":"Y Tian","year":"2025","unstructured":"Tian Y, Li J, Jin M, Piao Y, Sheng J, Mei Z, et al. Procedural sedative effect of remimazolam in ICU patients on invasive mechanical ventilation: a randomised, prospective study. Ann Intensive Care. 2025;15:8.","journal-title":"Ann Intensive Care"},{"key":"849_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-023-01974-9","volume":"23","author":"R Sekiguchi","year":"2023","unstructured":"Sekiguchi R, Kinoshita M, Kawanishi R, Kakuta N, Sakai Y, Tanaka K. Comparison of hemodynamics during induction of general anesthesia with remimazolam and target-controlled propofol in middle-aged and elderly patients: a single-center, randomized, controlled trial. BMC Anesthesiol. 2023;23:14.","journal-title":"BMC Anesthesiol"},{"key":"849_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.851","volume":"9","author":"T Liu","year":"2021","unstructured":"Liu T, Lai T, Chen J, Lu Y, He F, Chen Y, et al. Effect of remimazolam induction on hemodynamics in patients undergoing valve replacement surgery: a randomized, double-blind, controlled trial. Pharmacol Res Perspect. 2021;9:e00851.","journal-title":"Pharmacol Res Perspect"},{"key":"849_CR15","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1053\/j.jvca.2023.06.027","volume":"37","author":"Q Kuang","year":"2023","unstructured":"Kuang Q, Zhong N, Ye C, Zhu X, Wei F. Propofol versus remimazolam on cognitive function, hemodynamics, and oxygenation during one-lung ventilation in older patients undergoing pulmonary lobectomy: a randomized controlled trial. J Cardiothorac Vasc Anesth. 2023;37:1996\u20132005.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"849_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13840","volume":"51","author":"Y Yoshikawa","year":"2024","unstructured":"Yoshikawa Y, Oura S, Kanda M, Chaki T, Hirata N, Edanaga M, et al. Comparison of the negative effect of remimazolam and propofol on cardiac contractility: analysis of a randomised parallel-group trial and a preclinical ex vivo study. Clin Exp Pharmacol Physiol. 2024;51:e13840.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"849_CR17","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.2147\/DDDT.S504371","volume":"19","author":"D Wang","year":"2025","unstructured":"Wang D, Liu Z, Zhang W, Li S, Chen Y, Jiang C, et al. Comparison of remimazolam versus dexmedetomidine on hemodynamics in older patients under lower extremity orthopedic surgery with spinal anesthesia: a randomized controlled trial. Drug Des Devel Ther. 2025;19:6037\u201346.","journal-title":"Drug Des Devel Ther"},{"key":"849_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2024.115268","volume":"476","author":"L Zhou","year":"2025","unstructured":"Zhou L, Shi H, Xiao M, Liu W, Wang L, Zhou S, et al. Remimazolam attenuates lipopolysaccharide-induced neuroinflammation and cognitive dysfunction. Behav Brain Res. 2025;476:115268.","journal-title":"Behav Brain Res"},{"key":"849_CR19","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1007\/s11064-024-04115-x","volume":"49","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Yang Y, Wei Y, Xie Y. Remimazolam attenuates LPS-derived cognitive dysfunction via subdiaphragmatic vagus nerve target alpha7nAChR-mediated Nrf2\/HO-1 signal pathway. Neurochem Res. 2024;49:1306\u201321.","journal-title":"Neurochem Res"},{"key":"849_CR20","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s11845-025-04032-0","volume":"194","author":"Y Liu","year":"2025","unstructured":"Liu Y, Liu C, Zhou Q, Lu H, Pan P. Comparison of remimazolam besylate and dexmedetomidine on stress response and immune balance in patients with acute respiratory distress syndrome. Ir J Med Sci. 2025;194:1797\u2013803.","journal-title":"Ir J Med Sci"},{"key":"849_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108331","volume":"101","author":"H Fang","year":"2021","unstructured":"Fang H, Zhang Y, Wang J, Li L, An S, Huang Q, et al. Remimazolam reduces sepsis-associated acute liver injury by activation of peripheral benzodiazepine receptors and p38 inhibition of macrophages. Int Immunopharmacol. 2021;101:108331.","journal-title":"Int Immunopharmacol"},{"key":"849_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-03820-3","volume":"25","author":"B Zhou","year":"2025","unstructured":"Zhou B, Liu J, Jin L, Huang X. Remimazolam alleviates hepatic ischemia-reperfusion injury by activating FOXO1\/3 signaling: remimazolam alleviates hepatic ischemia reperfusion injury. BMC Gastroenterol. 2025;25:283.","journal-title":"BMC Gastroenterol"},{"key":"849_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176276","volume":"965","author":"H Xu","year":"2024","unstructured":"Xu H, Chen Y, Xie P, Lei T, Liu K, Liu X, et al. Remimazolam attenuates myocardial ischemia-reperfusion injury by inhibiting the NF-kB pathway of macrophage inflammation. Eur J Pharmacol. 2024;965:176276.","journal-title":"Eur J Pharmacol"},{"key":"849_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-024-02641-3","volume":"24","author":"Y Shi","year":"2024","unstructured":"Shi Y, Deng H, Zhang Z, Zhu X, Zeng Z. Remimazolam protects the liver from ischemia-reperfusion injury by inhibiting the MAPK\/ERK pathway. BMC Anesthesiol. 2024;24:251.","journal-title":"BMC Anesthesiol"},{"key":"849_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176342","volume":"966","author":"J Song","year":"2024","unstructured":"Song J, Yu W, Chen S, Huang J, Zhou C, Liang H. Remimazolam attenuates inflammation and kidney fibrosis following folic acid injury. Eur J Pharmacol. 2024;966:176342.","journal-title":"Eur J Pharmacol"},{"key":"849_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.739603","volume":"12","author":"X Liu","year":"2021","unstructured":"Liu X, Lin S, Zhong Y, Shen J, Zhang X, Luo S, et al. Remimazolam protects against LPS-induced endotoxicity improving survival of endotoxemia mice. Front Pharmacol. 2021;12:739603.","journal-title":"Front Pharmacol"},{"key":"849_CR27","volume":"1","author":"S Memtsoudis","year":"2019","unstructured":"Memtsoudis S, Cozowicz C, Zubizarreta N, Weinstein SM, Liu J, Kim DH, et al. Risk factors for postoperative delirium in patients undergoing lower extremity joint arthroplasty: A retrospective population-based cohort study. Reg Anesth Pain Med. 2019;1:100700.","journal-title":"Reg Anesth Pain Med"},{"key":"849_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-95379-y","volume":"15","author":"Y Wei","year":"2025","unstructured":"Wei Y, Pan S, Zhou Z, Yang Y, Liu T, Chen J, et al. Remimazolam attenuated lipopolysaccharide-induced behavioral deficits and neuronal injury via activation of the Nrf2 pathway. Sci Rep. 2025;15:13784.","journal-title":"Sci Rep"},{"key":"849_CR29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/ALN.0000000000005077","volume":"141","author":"YH Cai","year":"2024","unstructured":"Cai YH, Zhong JW, Ma HY, Szmuk P, Wang CY, Wang Z, et al. Effect of remimazolam on emergence delirium in children undergoing laparoscopic surgery: a double-blinded randomized trial. Anesthesiology. 2024;141:500\u201310.","journal-title":"Anesthesiology"},{"key":"849_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/anae.16475","volume":"80","author":"YB Fang","year":"2025","unstructured":"Fang YB, Zhong JW, Szmuk P, Lyu YL, Xu Y, Qu S, et al. Safety and efficacy of remimazolam tosilate for general anaesthesia in paediatric patients undergoing elective surgery: a multicentre, randomised, single-blind, controlled trial. Anaesthesia. 2025;80:259\u201368.","journal-title":"Anaesthesia"},{"key":"849_CR31","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.2147\/DDDT.S381611","volume":"16","author":"X Yang","year":"2022","unstructured":"Yang X, Lin C, Chen S, Huang Y, Cheng Q, Yao Y. Remimazolam for the prevention of emergence delirium in children following tonsillectomy and adenoidectomy under sevoflurane anesthesia: a randomized controlled study. Drug Des Devel Ther. 2022;16:3413\u201320.","journal-title":"Drug Des Devel Ther"},{"key":"849_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113464","volume":"143","author":"J Zhao","year":"2024","unstructured":"Zhao J, Yu T, He R, Li M, Xia W, Lu Y. Effects of remimazolam and surgery on cognition in a tibia fracture mouse model. Int Immunopharmacol. 2024;143:113464.","journal-title":"Int Immunopharmacol"},{"key":"849_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13741-025-00500-4","volume":"14","author":"L Yaqiu","year":"2025","unstructured":"Yaqiu L, Heng Z, Ruimin W, Xuri W. Effects of remimazolam and propofol on sleep rhythm and delirium after spinal surgery in elderly patients. Perioper Med. 2025;14:18.","journal-title":"Perioper Med"},{"key":"849_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04168-w","volume":"26","author":"Y Tang","year":"2022","unstructured":"Tang Y, Yang X, Yu Y, Shu H, Yuan Y, Liu H, et al. Remimazolam besylate versus propofol for long-term sedation during invasive mechanical ventilation: a pilot study. Crit Care. 2022;26:279.","journal-title":"Crit Care"},{"key":"849_CR35","doi-asserted-by":"publisher","DOI":"10.5492\/wjccm.v13.i3.96877","volume":"13","author":"PR Elmati","year":"2024","unstructured":"Elmati PR, Nagaradona T, Jagirdhar GSK, Surani S. Remimazolam in intensive care unit: potential applications and considerations. World J Crit Care Med. 2024;13:96877.","journal-title":"World J Crit Care Med"},{"key":"849_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1345656","volume":"14","author":"R Wang","year":"2024","unstructured":"Wang R, Li S, Hu H, Hou Q, Chu H, Hou Y, et al. Transcriptomic analysis and experiments revealed that remimazolam promotes proliferation and G1\/S transition in HCT8 cells. Front Oncol. 2024;14:1345656.","journal-title":"Front Oncol"},{"key":"849_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/13510002.2025.2475696","volume":"30","author":"HL Fan","year":"2025","unstructured":"Fan HL, Chen JL, Liu ST, Lee JT, Huang SM, Wu ZF, et al. Remimazolam induced cytotoxicity mediated through multiple stress pathways and acted synergistically with tyrosine kinase inhibitors in hepatocellular carcinoma. Redox Rep. 2025;30:2475696.","journal-title":"Redox Rep"}],"container-title":["Journal of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40560-026-00849-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-026-00849-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-026-00849-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:56:16Z","timestamp":1770987376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40560-026-00849-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1186\/s40560-026-00849-8","relation":{},"ISSN":["2052-0492"],"issn-type":[{"value":"2052-0492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable for this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}